Expertise in
6
conditions

Marisa M. Pinhata-Mussi

Bandeirantes Avenue 3900, 
Ribeirao Preto, SP, BR 
Expertise in
6
conditions
Bandeirantes Avenue 3900, 
Ribeirao Preto, SP, BR 

Overview

Marisa Pinhata-Mussi practices practicing medicine in Ribeirao Preto, Brazil.

Ms. Pinhata-Mussi is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Congenital Cytomegalovirus, Cytomegalovirus Infection, Cytomegalic Inclusion Disease, and Zika Virus Disease.

She is actively involved in clinical research, co-authoring 76 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Bandeirantes Avenue 3900, Ribeirao Preto, SP, Brazil
Other Locations
Otorhinolaryngology And Head And Neck Surgery, Sao Paulo, SP, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Enrollment Status: Completed
Publish Date: February 05, 2026
Intervention Type: Drug
Study Drugs: Dolutegravir, ABC/DTG/3TC
Study Phase: Phase 3
A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
Enrollment Status: Terminated
Publish Date: April 20, 2025
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
A Prospective Epidemiological Study of Pregnancy Outcomes and of Events of Interest in Pregnant Women, Neonates and Infants (PEPNI)
A Prospective Epidemiological Study of Pregnancy Outcomes and of Events of Interest in Pregnant Women, Neonates and Infants (PEPNI)
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Procedure, Other
Study Phase: Not Applicable
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

76 Total Publications

Cytomegalovirus Shedding in Brazilian Pregnant Women Living With HIV on Combination Antiretrovirals and CMV Infection in Infants.
Cytomegalovirus Shedding in Brazilian Pregnant Women Living With HIV on Combination Antiretrovirals and CMV Infection in Infants.
Journal: The Pediatric infectious disease journal
Published: August 26, 2026

Frequently Asked Questions about Marisa M. Pinhata-Mussi

Is Marisa M. Pinhata-Mussi a top-rated expert for Congenital Cytomegalovirus?

MediFind is an objective health platform that identifies experts based on real-world data. Marisa M. Pinhata-Mussi is classified as an Distinguished expert for Congenital Cytomegalovirus, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marisa M. Pinhata-Mussi participate in research or clinical trials?

Yes. Marisa M. Pinhata-Mussi has published 76 articles and abstracts on conditions like Congenital Cytomegalovirus. You can view a list of Marisa M. Pinhata-Mussi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pinhata-Mussi's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile